tradingkey.logo


MaxCyte Inc

MXCT
1.630USD
+0.130+8.67%
āļ›āļīāļ” 12/22, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
173.83MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ MaxCyte Inc āļšāļĢāļīāļĐāļąāļ—

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

āļ‚āđ‰āļ­āļĄāļđāļĨ MaxCyte Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™MXCT
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—MaxCyte Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļMar 29, 2016
āļ‹āļĩāļ­āļĩāđ‚āļ­Masoud (Maher)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™114
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Mar 29
āļ—āļĩāđˆāļ­āļĒāļđāđˆ9713 Key West Avenue,
āđ€āļĄāļ·āļ­āļ‡ROCKVILLE
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ20850
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ13015175556
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.maxcyte.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™MXCT
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļMar 29, 2016
āļ‹āļĩāļ­āļĩāđ‚āļ­Masoud (Maher)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ MaxCyte Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
+86.70%
Ms. Cynthia L. Collins
Ms. Cynthia L. Collins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
FY2025Q2
FY2025Q1
FY2024
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Product sales
5.27M
61.94%
Licenses
2.93M
34.42%
other
310.00K
3.64%
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Product sales
5.27M
61.94%
Licenses
2.93M
34.42%
other
310.00K
3.64%

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 1 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 1 āļ˜.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Cadian Capital Management LP
7.71%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.24%
River Global Investors LLP
5.15%
āļ­āļ·āđˆāļ™ āđ†
66.67%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Cadian Capital Management LP
7.71%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.24%
River Global Investors LLP
5.15%
āļ­āļ·āđˆāļ™ āđ†
66.67%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor/Hedge Fund
24.33%
Investment Advisor
22.61%
Hedge Fund
17.87%
Research Firm
4.86%
Private Equity
4.73%
Individual Investor
1.74%
Venture Capital
0.36%
Bank and Trust
0.19%
Pension Fund
0.15%
āļ­āļ·āđˆāļ™ āđ†
23.16%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 1 āļ•.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 1 āļ•.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q3
287
82.96M
77.85%
-17.02M
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
2023Q2
284
79.82M
77.43%
-11.81M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Cadian Capital Management LP
8.91M
8.36%
-1.11M
-11.10%
Jun 30, 2025
Mirabella Financial Services LLP
6.60M
6.19%
+2.90M
+78.38%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.21M
7.7%
+793.69K
+10.70%
Jun 30, 2025
The Vanguard Group, Inc.
5.60M
5.25%
+36.02K
+0.65%
Jun 30, 2025
River Global Investors LLP
3.25M
3.05%
+1.19M
+57.73%
Dec 31, 2024
Vitruvian Partners LLP
5.04M
4.73%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
4.23M
3.97%
+795.36K
+23.12%
Jun 30, 2025
Mudita Advisors LLP
3.37M
3.16%
+42.25K
+1.27%
Jun 30, 2025
AXA Investment Managers UK Ltd.
2.20M
2.07%
+1.22M
+123.16%
Jun 30, 2025
AXA Investment Managers Paris
2.20M
2.07%
--
--
Jul 31, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Invesco NASDAQ Future Gen 200 ETF
0.6%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
Invesco NASDAQ Future Gen 200 ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.6%
iShares Micro-Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.03%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.02%
Avantis US Small Cap Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.02%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.02%
iShares Russell 2000 Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
Proshares Ultra Russell 2000
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
iShares Russell 2000 ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
Global X Russell 2000 ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
iShares Biotechnology ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ MaxCyte Inc?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ MaxCyte Inc āđ„āļ”āđ‰āđāļāđˆ:
Cadian Capital Management LP āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 8.91M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 8.36% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Mirabella Financial Services LLP āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 6.60M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 6.19% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
BlackRock Institutional Trust Company, N.A. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 8.21M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 7.70% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
The Vanguard Group, Inc. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 5.60M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 5.25% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
River Global Investors LLP āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 3.25M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 3.05% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”

āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ MaxCyte Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ MaxCyte Inc āđ„āļ”āđ‰āđāļāđˆ
Cadian Capital Management LP
Mirabella Financial Services LLP
BlackRock Institutional Trust Company, N.A.

āļĄāļĩāļāļĩāđˆāļŠāļ–āļēāļšāļąāļ™āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ MaxCyte Inc (MXCT)?


āļ“ āļ§āļąāļ™āļ—āļĩāđˆ 2025Q3 āļĄāļĩāļŠāļ–āļēāļšāļąāļ™āļˆāļģāļ™āļ§āļ™ 287 āđāļŦāđˆāļ‡āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ MaxCyte Inc āđ‚āļ”āļĒāļĄāļĩāļĄāļđāļĨāļ„āđˆāļēāļĢāļ§āļĄāļ›āļĢāļ°āļĄāļēāļ“ 82.96M āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 77.85% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ” āđ€āļĄāļ·āđˆāļ­āđ€āļ—āļĩāļĒāļšāļāļąāļšāļ§āļąāļ™āļ—āļĩāđˆ 2025Q2 āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āđ„āļ”āđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ 3.93%

āđāļŦāļĨāđˆāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŦāļĨāļąāļāļ‚āļ­āļ‡ MaxCyte Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āđ€āļĄāļ·āđˆāļ­āļ§āļąāļ™āļ—āļĩāđˆ FY2025Q2 āļ˜āļļāļĢāļāļīāļˆāļ”āđ‰āļēāļ™ Product sales āļŠāļĢāđ‰āļēāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŠāļđāļ‡āļŠāļļāļ”āđƒāļŦāđ‰āļāļąāļš MaxCyte Inc āļ„āļīāļ”āđ€āļ›āđ‡āļ™āļĄāļđāļĨāļ„āđˆāļē 5.27M āđāļĨāļ°āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 61.94% āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļĢāļ§āļĄ
KeyAI
î™